IDRI and Zydus Sign Agreement for Development of IDRI’s Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar)

July 25th, 2013|Press Releases|

Seattle, WA | July 25, 2013 Seattle, WA, and Ahmedabad, India, July 25, 2013: – In a unique partnership, Zydus, India’s fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product [...]

IDRI Moves into New Space at 1616 Eastlake

May 7th, 2013|Press Releases|

Seattle, WA | May 7, 2013 Seattle, WA, May 7, 2013: IDRI (Infectious Disease Research Institute) has officially moved from its long-time residence in Seattle’s First Hill neighborhood to its new home at 1616 Eastlake Avenue East, where it [...]

IDRI and Medicago Report Positive Results for Phase 1 Clinical Trial for an H5N1 Vaccine

April 17th, 2013|Press Releases|

Seattle, WA | April 17, 2013 SEATTLE, WA, and QUEBEC CITY, QC, April 17, 2013 – IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, [...]

IDRI and Medicago to Present Data at the World Vaccine Congress

April 8th, 2013|Press Releases|

Seattle, WA | April 8, 2013 SEATTLE, WA, and QUEBEC CITY, QC, April 9, 2013 – IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, [...]

IDRI and Orangelife Register Rapid Diagnostic for Leprosy for Use in Brazil

January 24th, 2013|Press Releases|

Seattle, WA | January 24, 2013 IDRI (Infectious Disease Research Institute), in conjunction with OrangeLife, a Brazilian diagnostic company, today announces the registration of a rapid diagnostic test for leprosy, offering new hope for early diagnosis and treatment. The [...]

Tuberculosis Vaccine Candidate to Prevent Disease Enters Clinical Testing

August 22nd, 2012|Press Releases|

Seattle, WA | August 22, 2012 Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI’s novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess [...]

IDRI and Medicago Announce FDA Authorization to Initiate a Phase 1 Clinical Trial for an H5N1 Vaccine with GLA Adjuvant

August 16th, 2012|Press Releases|

Seattle, WA | August 16, 2012 The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical [...]

IDRI Receives $3.7 Million Grant for TB Drug Discovery

July 25th, 2012|Press Releases|

Seattle, WA | July 25, 2012 IDRI's drug discovery efforts continue to grow with a recently awarded five-year grant for $3.7 million from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The [...]

IDRI Expands Board, Adding Additional International Expertise

July 2nd, 2012|Press Releases|

Seattle, WA | July 2, 2012 The Infectious Disease Research Institute (IDRI) continues to expand its Board of Directors, comprised of international leaders in industry and academia, with the recent addition of Massimo Radaelli, Ph.D., who has 25 years [...]

Seven Pharmaceutical Companies Join Academic Researchers to Speed TB Drug Discovery

June 25th, 2012|Press Releases|

June 25, 2012 Seven pharmaceutical companies and four research institutions, working with the Bill & Melinda Gates Foundation, have launched a groundbreaking partnership that aims to speed the discovery of essential new treatments for tuberculosis (TB). The partnership, known [...]

Load More